Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia
Summary We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete r...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2023-08, Vol.202 (4), p.856-865 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 865 |
|---|---|
| container_issue | 4 |
| container_start_page | 856 |
| container_title | British journal of haematology |
| container_volume | 202 |
| creator | Huo, Wen‐Xuan Wen, Qi Zhang, Xiao‐Hui Xu, Lan‐Ping Wang, Yu Yan, Chen‐Hua Chen, Huan Chen, Yu‐Hong Han, Wei Wang, Feng‐Rong Wang, Jing‐Zhi Huang, Xiao‐Jun Mo, Xiao‐Dong |
| description | Summary
We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR.
The 3‐year probabolities of overall survival after haploidentical related donor haematopoitic stem cell transplantation according to (A) favourable‐, intermidiate‐ and poor‐risk acute myeloid leukaemia category at diagnosis and (B) low‐ intermidiate‐ and high‐risk haematopoietic stem cell transplantation‐specific comorbidity index scores before allo‐ haematopoietic stem cell transplantation. |
| doi_str_mv | 10.1111/bjh.18937 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2830217557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2830217557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-d3d18923035d540854b6a17f1e56e7d91a653421b18af17a141fd349c4eb7ebc3</originalsourceid><addsrcrecordid>eNp1kUFvFCEUx4mpsWv10C9gSHrRw7S8AYbZo92o1TTpRc8TBt50WZlhOkCavfnRZd3ag4lcCC8_fvDen5BzYJdQ1lW_215Cu-bqBVkBb2RVg4ATsmKMqQqYaE_J6xh3jAFnEl6RU64KBUKtyK-7nEwYMdIw0K2efXAWp-SM9uWIo05hDg5LgcaEIzXoPU2LnuLs9ZR0cmGiQ1iotsFjNOUu1ZOl-5Cn-1LMPkX66NKWapMT0nGPhyeox_yz6J1-Q14O2kd8-7SfkR-fP33f3FS3d1--bj7eVoZLrirLbemw5oxLKwVrpegbDWoAlA0quwbdSC5q6KHVAyhdBjBYLtZGYK-wN_yMvD965yU8ZIypG108dKMnDDl2dctZDUpKVdCLf9BdyMtUfleoMjbRNLAu1IcjZZYQ44JDNy9u1Mu-A9YdYulKLN2fWAr77smY-xHtM_k3hwJcHYFH53H_f1N3_e3mqPwNbJaYUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2851446619</pqid></control><display><type>article</type><title>Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Huo, Wen‐Xuan ; Wen, Qi ; Zhang, Xiao‐Hui ; Xu, Lan‐Ping ; Wang, Yu ; Yan, Chen‐Hua ; Chen, Huan ; Chen, Yu‐Hong ; Han, Wei ; Wang, Feng‐Rong ; Wang, Jing‐Zhi ; Huang, Xiao‐Jun ; Mo, Xiao‐Dong</creator><creatorcontrib>Huo, Wen‐Xuan ; Wen, Qi ; Zhang, Xiao‐Hui ; Xu, Lan‐Ping ; Wang, Yu ; Yan, Chen‐Hua ; Chen, Huan ; Chen, Yu‐Hong ; Han, Wei ; Wang, Feng‐Rong ; Wang, Jing‐Zhi ; Huang, Xiao‐Jun ; Mo, Xiao‐Dong</creatorcontrib><description>Summary
We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR.
The 3‐year probabolities of overall survival after haploidentical related donor haematopoitic stem cell transplantation according to (A) favourable‐, intermidiate‐ and poor‐risk acute myeloid leukaemia category at diagnosis and (B) low‐ intermidiate‐ and high‐risk haematopoietic stem cell transplantation‐specific comorbidity index scores before allo‐ haematopoietic stem cell transplantation.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18937</identifier><identifier>PMID: 37365147</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>acute myeloid leukaemia ; Acute myeloid leukemia ; adolescent and young adults ; allogeneic haematopoietic stem cell transplantation ; Comorbidity ; haploidentical ; Hematology ; Hematopoietic stem cells ; Leukemia ; Mortality ; Remission ; Stem cell transplantation ; Young adults</subject><ispartof>British journal of haematology, 2023-08, Vol.202 (4), p.856-865</ispartof><rights>2023 British Society for Haematology and John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-d3d18923035d540854b6a17f1e56e7d91a653421b18af17a141fd349c4eb7ebc3</citedby><cites>FETCH-LOGICAL-c3537-d3d18923035d540854b6a17f1e56e7d91a653421b18af17a141fd349c4eb7ebc3</cites><orcidid>0009-0006-1392-2081 ; 0000-0002-9881-7945 ; 0000-0003-0245-6792 ; 0000-0003-1253-7465</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18937$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18937$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37365147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huo, Wen‐Xuan</creatorcontrib><creatorcontrib>Wen, Qi</creatorcontrib><creatorcontrib>Zhang, Xiao‐Hui</creatorcontrib><creatorcontrib>Xu, Lan‐Ping</creatorcontrib><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Yan, Chen‐Hua</creatorcontrib><creatorcontrib>Chen, Huan</creatorcontrib><creatorcontrib>Chen, Yu‐Hong</creatorcontrib><creatorcontrib>Han, Wei</creatorcontrib><creatorcontrib>Wang, Feng‐Rong</creatorcontrib><creatorcontrib>Wang, Jing‐Zhi</creatorcontrib><creatorcontrib>Huang, Xiao‐Jun</creatorcontrib><creatorcontrib>Mo, Xiao‐Dong</creatorcontrib><title>Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR.
The 3‐year probabolities of overall survival after haploidentical related donor haematopoitic stem cell transplantation according to (A) favourable‐, intermidiate‐ and poor‐risk acute myeloid leukaemia category at diagnosis and (B) low‐ intermidiate‐ and high‐risk haematopoietic stem cell transplantation‐specific comorbidity index scores before allo‐ haematopoietic stem cell transplantation.</description><subject>acute myeloid leukaemia</subject><subject>Acute myeloid leukemia</subject><subject>adolescent and young adults</subject><subject>allogeneic haematopoietic stem cell transplantation</subject><subject>Comorbidity</subject><subject>haploidentical</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Leukemia</subject><subject>Mortality</subject><subject>Remission</subject><subject>Stem cell transplantation</subject><subject>Young adults</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kUFvFCEUx4mpsWv10C9gSHrRw7S8AYbZo92o1TTpRc8TBt50WZlhOkCavfnRZd3ag4lcCC8_fvDen5BzYJdQ1lW_215Cu-bqBVkBb2RVg4ATsmKMqQqYaE_J6xh3jAFnEl6RU64KBUKtyK-7nEwYMdIw0K2efXAWp-SM9uWIo05hDg5LgcaEIzXoPU2LnuLs9ZR0cmGiQ1iotsFjNOUu1ZOl-5Cn-1LMPkX66NKWapMT0nGPhyeox_yz6J1-Q14O2kd8-7SfkR-fP33f3FS3d1--bj7eVoZLrirLbemw5oxLKwVrpegbDWoAlA0quwbdSC5q6KHVAyhdBjBYLtZGYK-wN_yMvD965yU8ZIypG108dKMnDDl2dctZDUpKVdCLf9BdyMtUfleoMjbRNLAu1IcjZZYQ44JDNy9u1Mu-A9YdYulKLN2fWAr77smY-xHtM_k3hwJcHYFH53H_f1N3_e3mqPwNbJaYUw</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Huo, Wen‐Xuan</creator><creator>Wen, Qi</creator><creator>Zhang, Xiao‐Hui</creator><creator>Xu, Lan‐Ping</creator><creator>Wang, Yu</creator><creator>Yan, Chen‐Hua</creator><creator>Chen, Huan</creator><creator>Chen, Yu‐Hong</creator><creator>Han, Wei</creator><creator>Wang, Feng‐Rong</creator><creator>Wang, Jing‐Zhi</creator><creator>Huang, Xiao‐Jun</creator><creator>Mo, Xiao‐Dong</creator><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0006-1392-2081</orcidid><orcidid>https://orcid.org/0000-0002-9881-7945</orcidid><orcidid>https://orcid.org/0000-0003-0245-6792</orcidid><orcidid>https://orcid.org/0000-0003-1253-7465</orcidid></search><sort><creationdate>202308</creationdate><title>Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia</title><author>Huo, Wen‐Xuan ; Wen, Qi ; Zhang, Xiao‐Hui ; Xu, Lan‐Ping ; Wang, Yu ; Yan, Chen‐Hua ; Chen, Huan ; Chen, Yu‐Hong ; Han, Wei ; Wang, Feng‐Rong ; Wang, Jing‐Zhi ; Huang, Xiao‐Jun ; Mo, Xiao‐Dong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-d3d18923035d540854b6a17f1e56e7d91a653421b18af17a141fd349c4eb7ebc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>acute myeloid leukaemia</topic><topic>Acute myeloid leukemia</topic><topic>adolescent and young adults</topic><topic>allogeneic haematopoietic stem cell transplantation</topic><topic>Comorbidity</topic><topic>haploidentical</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Leukemia</topic><topic>Mortality</topic><topic>Remission</topic><topic>Stem cell transplantation</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huo, Wen‐Xuan</creatorcontrib><creatorcontrib>Wen, Qi</creatorcontrib><creatorcontrib>Zhang, Xiao‐Hui</creatorcontrib><creatorcontrib>Xu, Lan‐Ping</creatorcontrib><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Yan, Chen‐Hua</creatorcontrib><creatorcontrib>Chen, Huan</creatorcontrib><creatorcontrib>Chen, Yu‐Hong</creatorcontrib><creatorcontrib>Han, Wei</creatorcontrib><creatorcontrib>Wang, Feng‐Rong</creatorcontrib><creatorcontrib>Wang, Jing‐Zhi</creatorcontrib><creatorcontrib>Huang, Xiao‐Jun</creatorcontrib><creatorcontrib>Mo, Xiao‐Dong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huo, Wen‐Xuan</au><au>Wen, Qi</au><au>Zhang, Xiao‐Hui</au><au>Xu, Lan‐Ping</au><au>Wang, Yu</au><au>Yan, Chen‐Hua</au><au>Chen, Huan</au><au>Chen, Yu‐Hong</au><au>Han, Wei</au><au>Wang, Feng‐Rong</au><au>Wang, Jing‐Zhi</au><au>Huang, Xiao‐Jun</au><au>Mo, Xiao‐Dong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>202</volume><issue>4</issue><spage>856</spage><epage>865</epage><pages>856-865</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR.
The 3‐year probabolities of overall survival after haploidentical related donor haematopoitic stem cell transplantation according to (A) favourable‐, intermidiate‐ and poor‐risk acute myeloid leukaemia category at diagnosis and (B) low‐ intermidiate‐ and high‐risk haematopoietic stem cell transplantation‐specific comorbidity index scores before allo‐ haematopoietic stem cell transplantation.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>37365147</pmid><doi>10.1111/bjh.18937</doi><tpages>10</tpages><orcidid>https://orcid.org/0009-0006-1392-2081</orcidid><orcidid>https://orcid.org/0000-0002-9881-7945</orcidid><orcidid>https://orcid.org/0000-0003-0245-6792</orcidid><orcidid>https://orcid.org/0000-0003-1253-7465</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2023-08, Vol.202 (4), p.856-865 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2830217557 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete |
| subjects | acute myeloid leukaemia Acute myeloid leukemia adolescent and young adults allogeneic haematopoietic stem cell transplantation Comorbidity haploidentical Hematology Hematopoietic stem cells Leukemia Mortality Remission Stem cell transplantation Young adults |
| title | Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T01%3A31%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20haploidentical%20haematopoietic%20stem%20cell%20transplantation%20for%20adolescent%20and%20young%20adults%20with%20acute%20myeloid%20leukaemia&rft.jtitle=British%20journal%20of%20haematology&rft.au=Huo,%20Wen%E2%80%90Xuan&rft.date=2023-08&rft.volume=202&rft.issue=4&rft.spage=856&rft.epage=865&rft.pages=856-865&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18937&rft_dat=%3Cproquest_cross%3E2830217557%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2851446619&rft_id=info:pmid/37365147&rfr_iscdi=true |